FY2026 Earnings Estimate for Alector Issued By HC Wainwright

Alector, Inc. (NASDAQ:ALEC) – Investment analysts at HC Wainwright upped their FY2026 earnings per share estimates for Alector in a research report issued on Wednesday, October 14th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.03) per share for the year, up from their previous estimate of ($0.93). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Alector’s current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Alector’s Q4 2026 earnings at $0.62 EPS, FY2028 earnings at ($0.82) EPS and FY2030 earnings at ($0.75) EPS.

Alector (NASDAQ:ALEC) last posted its earnings results on Thursday, August 6th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. The firm had revenue of $3.32 million during the quarter, compared to analysts’ expectations of $1.71 million. Alector had a negative net margin of 850.13% and a negative return on equity of 531.03%.

A number of other equities analysts have also recently issued reports on ALEC. Weiss Ratings upgraded shares of Alector from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. UBS Group reissued a “neutral” rating and issued a $1.50 price objective on shares of Alector in a research note on Tuesday, October 6th. Finally, Morgan Stanley raised their target price on shares of Alector from $2.00 to $3.00 and gave the company an “underweight” rating in a research report on Tuesday, October 6th. Three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Alector Price Performance

ALEC opened at $1.91 on Friday. The company’s 50 day moving average is $2.11 and its 200-day moving average is $2.03. Alector has a 1-year low of $1.09 and a 1-year high of $3.40. The company has a debt-to-equity ratio of 0.80, a quick ratio of 5.26 and a current ratio of 5.26.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Alector in the 2nd quarter valued at about $15,774,000. Nantahala Capital Management LLC bought a new position in shares of Alector during the 2nd quarter worth about $8,679,399. Merck & Co. Inc. acquired a new stake in shares of Alector in the 2nd quarter valued at about $7,126,896. 683 Capital Management LLC grew its stake in shares of Alector by 235.0% in the 4th quarter. 683 Capital Management LLC now owns 3,350,000 shares of the company’s stock valued at $5,226,000 after buying an additional 2,350,000 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Alector in the 2nd quarter valued at about $5,796,000. Institutional investors own 85.83% of the company’s stock.

Insider Activity at Alector

In other news, CEO Arnon Rosenthal sold 72,606 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $2.66, for a total value of $193,131.96. Following the completion of the transaction, the chief executive officer owned 2,294,600 shares of the company’s stock, valued at $6,103,636. This represents a 3.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Neil Berkley sold 29,251 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $2.66, for a total transaction of $77,807.66. Following the completion of the transaction, the chief financial officer owned 350,649 shares of the company’s stock, valued at approximately $932,726.34. This trade represents a 7.70% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 111,303 shares of company stock valued at $295,633 in the last ninety days. 8.30% of the stock is currently owned by insiders.

About Alector

Alector, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s approach, known as immuno-neurology, seeks to use the immune system to protect brain health and address biological mechanisms involved in conditions such as Alzheimer’s disease, frontotemporal dementia and Parkinson’s disease.

Alector’s pipeline includes latozinemab, an antibody designed to increase levels of progranulin, a protein associated with the health and function of brain cells.